PriceTargets.com logo

Galmed Pharmaceuticals - GLMD Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$3.05 As of 12/20/2024 06:16 PM ET
▼ -0.02 (-0.65%)

This chart shows the closing price for GLMD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Galmed Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GLMD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GLMD

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Galmed Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $3.05.

This chart shows the closing price for GLMD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Galmed Pharmaceuticals. This rating has held steady since July 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/24/2023Maxim GroupUpgradeHold ➝ Buy
8/8/2022Maxim GroupDowngradeBuy ➝ Hold
8/8/2022Canaccord Genuity GroupDowngradeBuy ➝ Hold
8/4/2022Cantor FitzgeraldDowngradeOverweight ➝ Neutral
5/18/2022Raymond JamesDowngradeOutperform ➝ Market Perform
5/4/2022Canaccord Genuity GroupLower Target$4,320.00 ➝ $900.00
5/3/2022HC WainwrightDowngradeBuy ➝ Neutral
3/19/2021HC WainwrightLower TargetBuy$5,220.00 ➝ $4,500.00
1/8/2021Raymond JamesLower TargetOutperform$3,600.00 ➝ $3,060.00
11/13/2020Cantor FitzgeraldReiterated RatingOverweight
7/12/2020Roth CapitalReiterated RatingBuy ➝ Market Perform$5,940.00
7/12/2020Cantor FitzgeraldReiterated RatingOverweight$2,520.00
5/22/2020B. RileyDowngradeBuy ➝ Neutral$1,980.00 ➝ $1,440.00
5/15/2020Maxim GroupInitiated CoverageBuy$1,800.00
5/15/2020Raymond JamesLower TargetOutperform$4,500.00 ➝ $3,600.00
5/15/2020HC WainwrightLower TargetBuy$6,120.00 ➝ $5,220.00
3/13/2020HC WainwrightReiterated RatingBuy
3/13/2020Stifel NicolausLower TargetBuy$6,300.00 ➝ $4,500.00
3/13/2020B. RileyLower TargetBuy$5,040.00 ➝ $1,980.00
2/4/2020Craig HallumInitiated CoverageBuy$3,240.00
1/30/2020Cantor FitzgeraldLower TargetOverweight$10,620.00 ➝ $2,520.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 1 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Galmed Pharmaceuticals logo
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.
Read More

Today's Range

Now: $3.05
Low: $2.89
High: $3.32

50 Day Range

MA: $3.23
Low: $2.56
High: $4.81

52 Week Range

Now: $3.05
Low: $2.56
High: $23.80

Volume

72,111 shs

Average Volume

701,191 shs

Market Capitalization

$1.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.75

Frequently Asked Questions

What sell-side analysts currently cover shares of Galmed Pharmaceuticals?

The following sell-side analysts have issued stock ratings on Galmed Pharmaceuticals in the last year: StockNews.com.
View the latest analyst ratings for GLMD.

What is the current price target for Galmed Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Galmed Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Galmed Pharmaceuticals in the next year.
View the latest price targets for GLMD.

What is the current consensus analyst rating for Galmed Pharmaceuticals?

Galmed Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for GLMD.

What other companies compete with Galmed Pharmaceuticals?

Other companies that are similar to Galmed Pharmaceuticals include Ensysce Biosciences, ObsEva, Conduit Pharmaceuticals, CERo Therapeutics and Soligenix. Learn More about companies similar to Galmed Pharmaceuticals.

How do I contact Galmed Pharmaceuticals' investor relations team?

Galmed Pharmaceuticals' physical mailing address is 16 TIOMKIN STREET, TEL AVIV L3, 6578317. The biopharmaceutical company's listed phone number is (723) 693-8448 and its investor relations email address is [email protected]. The official website for Galmed Pharmaceuticals is www.galmedpharma.com. Learn More about contacing Galmed Pharmaceuticals investor relations.